1. 136P Profiling the tumour immune microenvironment in pleomorphic dermal sarcomas suggests its potential effectiveness for immunotherapy. (15th December 2019) Authors: Noh, K-W; Klein, S; Mauch, C; Wagener-Ryzek, S; Schoemmel, M; Buettner, R; Quaas, A; Helbig, D Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P14.06 Radiomics for the non-invasive determination of the BRAF mutational status in patients with melanoma brain metastases. (9th September 2021) Authors: Meissner, A; Gutsche, R; Galldiks, N; Kocher, M; Juenger, S T; Wendl, C; Mauch, C; Proescholdt, M; Grau, S; Lohmann, P Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. (14th November 2018) Authors: Urbonas, V; Schadendorf, D; Zimmer, L; Danson, S; Marshall, E; Corrie, P; Wheater, M; Plummer, E; Mauch, C; Scudder, C; Goff, M; Love, S B; Mohammed, S B; Middleton, M R Journal: Annals of oncology Issue: Volume 30:Number 2(2019) Page Start: 317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗